Benzinga | Jun 9, 2021 07:18AM EDT

Adaptive Biotechnologies Corporation Highlights Publication Of Study Using immunoSEQ T-MAP COVID

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced that immunoSEQ(r) T-MAP(tm) COVID was used in the Nature study to measure the T-cell immune response elicited by the Johnson & Johnson COVID-19 vaccine in the context of multiple variants of SARS-CoV-2, including B 1.351 and B.1.1.7. The study provides further evidence that the T-cell response may contribute to protection from COVID-19. Adaptive's Technology was used to quantify T-cell expansion across all regions of the virus, demonstrating that the T-cell response is broad and unaltered by mutations that render vaccine-generated antibodies less effective. The study was conducted by Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA.